UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PLAYTIKA HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 81-3634591 (State of other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) c/o Playtika Ltd. HaChoshlim St 8 Herzliya Pituach, Israel 972-73-316-3251 (Address, including zip code, and telephone number, includ ...

Exhibit 99.1 Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update WATERTOWN, Mass., August 7, 2025 – Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a recap of recent program and corporate developments. "We are please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission file number 1-03480 MDU RESOURCES GROUP, INC. (Exact name of registrant as specified in its charter) (Registrant's telephone nu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37872 Priority Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4257046 (State or other jurisdi ...

[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements for Q2 and H1 2025, including balance sheets, operations, cash flows, and detailed notes [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to **$279.0 million** while total liabilities increased to **$218.1 million**, driven by operating lease liabilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $53,804 | $182,476 | | Total current assets | $121,287 | $211,886 | | Total assets | $279,009 | $297,508 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $34,109 | $37,961 | | Operating lease liability, net of current | $112,478 | $37,180 | | Total liabilities | $218,149 | $144,359 | | Total stockholders' equity | $60,860 | $153,149 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q2 2025 saw **$1.1 million** in revenue and a **$52.6 million** net loss, while H1 2025 net loss was **$104.5 million** Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $1,115 | $0 | $2,569 | $591 | | Research and development | $41,375 | $43,071 | $81,937 | $80,845 | | General and administrative | $13,117 | $12,601 | $26,401 | $23,759 | | Loss from operations | $(53,377) | $(55,672) | $(105,769) | $(104,013) | | Net loss | $(52,591) | $(55,327) | $(104,481) | $(101,088) | | Net loss per share | $(0.41) | $(0.46) | $(0.81) | $(0.90) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2025 net cash used in operating activities was **$90.3 million**, with financing activities providing **$6.2 million**, ending the period with **$67.5 million** in cash Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(90,269) | $(113,198) | | Net cash used in investing activities | $(44,971) | $(30,138) | | Net cash provided by financing activities | $6,197 | $157,362 | | **Net change in cash, cash equivalents, and restricted cash** | **$(129,043)** | **$14,026** | | Cash, cash equivalents, and restricted cash at end of period | $67,495 | $69,096 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail liquidity, accounting policies, and key agreements, including a **$138.2 million** stock offering, stock option repricing, and ongoing arbitration with Beam Therapeutics - In August 2025, the company raised approximately **$138.2 million** in net proceeds from a common stock offering, which is expected to be sufficient to fund operations for at least the next twelve months[34](index=34&type=chunk)[35](index=35&type=chunk) - On August 1, 2025, the company repriced certain outstanding employee and director stock options with exercise prices above **$4.04** down to **$4.04** per share to improve retention and incentive value[80](index=80&type=chunk)[81](index=81&type=chunk) - The company is in an arbitration proceeding with Beam Therapeutics, Inc regarding a dispute over the development of a treatment for alpha-1 antitrypsin deficiency (AATD)[89](index=89&type=chunk)[141](index=141&type=chunk) - In July 2025, the company entered into an agreement with the Cystic Fibrosis Foundation (CFF) for up to **$24 million** in additional funding to accelerate the development of Prime Editors for cystic fibrosis[87](index=87&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the strategic shift to the in vivo liver franchise, analyzes Q2 and H1 2025 financial results, and highlights a **$138.2 million** financing extending the cash runway into 2027 [Overview and Business Update](index=27&type=section&id=Overview%20and%20Business%20Update) The company strategically refocused on its in vivo liver franchise (Wilson's Disease, AATD) with 2026 IND/CTA filings, while continuing CF and CAR-T programs and seeking partners for PM359 - Strategic focus has shifted to the in vivo liver franchise, targeting Wilson's Disease and AATD, with IND/CTA filings anticipated in the first half and middle of 2026, respectively[94](index=94&type=chunk) - The company will continue its Cystic Fibrosis program, supported by up to **$24 million** in additional funding from the Cystic Fibrosis Foundation, and its CAR-T collaboration with Bristol-Myers Squibb[95](index=95&type=chunk)[96](index=96&type=chunk) - Initial data from the Phase 1/2 trial of PM359 for CGD showed high levels of dihydrorhodamine positivity, considered potentially curative; the company is now seeking partners for this program following its strategic shift[97](index=97&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Q2 2025 R&D expenses decreased by **$1.7 million** due to program deprioritization, while H1 2025 G&A expenses increased by **$2.6 million** from severance and legal fees R&D Expense Comparison - Q2 (in thousands) | Category | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Personnel expenses | $14,448 | $16,198 | $(1,750) | | Facility related | $13,765 | $11,302 | $2,463 | | Research costs | $8,116 | $11,390 | $(3,274) | | **Total R&D expenses** | **$41,375** | **$43,071** | **$(1,696)** | G&A Expense Comparison - H1 (in thousands) | Category | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Personnel expenses | $14,238 | $12,840 | $1,398 | | Professional and consultant fees | $7,228 | $5,931 | $1,297 | | **Total G&A expenses** | **$26,401** | **$23,759** | **$2,642** | - The decrease in Q2 R&D spending was driven by a **$3.3 million** reduction in research costs and a **$1.1 million** drop in clinical expenses due to the deprioritization of the CGD program[107](index=107&type=chunk) - The increase in H1 G&A expenses was primarily due to a **$1.4 million** increase in personnel costs related to one-time severance payments from the workforce reduction and a **$1.3 million** increase in corporate legal fees[112](index=112&type=chunk)[116](index=116&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held **$101.8 million** in cash and investments, supplemented by a **$138.2 million** August 2025 stock offering, extending its cash runway into 2027 - As of June 30, 2025, the company held **$101.8 million** in cash, cash equivalents, and investments[117](index=117&type=chunk) - An August 2025 stock offering generated approximately **$138.2 million** in net proceeds, extending the company's cash runway into 2027[118](index=118&type=chunk)[126](index=126&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its **$115.4 million** investment portfolio, though a 10% rate change is not expected to be material - The company is exposed to interest rate risk on its **$115.4 million** portfolio of cash, cash equivalents, investments, and restricted cash[135](index=135&type=chunk) - Management does not believe a 10% change in interest rates would materially affect the fair market value of its investments due to their short-term nature[135](index=135&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) As of June 30, 2025, the company's disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during Q2 2025 - The company's disclosure controls and procedures were deemed effective as of the end of the period covered by this report (June 30, 2025)[138](index=138&type=chunk) - No changes occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[139](index=139&type=chunk) [PART II - OTHER INFORMATION](index=34&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company is in arbitration with Beam Therapeutics over alleged breach of a collaboration agreement regarding the AATD program, with Beam seeking damages and program transfer - The company is in a consolidated arbitration proceeding with Beam Therapeutics regarding the development of a treatment for AATD[141](index=141&type=chunk) - Beam alleges breach of contract and seeks declaratory, injunctive, and monetary relief, which could include forcing the company to cease work on its AATD program and transfer it to Beam[141](index=141&type=chunk) [Item 1A. Risk Factors](index=34&type=page&id=Item%201A.%20Risk%20Factors) Updated risk factors include healthcare reform, U.S. tax/trade policy changes, challenges in retaining key personnel, collaborator disputes, and operational risks from the May 2025 restructuring - Healthcare reform, including the Inflation Reduction Act of 2022 (IRA), could increase costs, add downward pressure on drug prices, and adversely affect profitability[143](index=143&type=chunk)[147](index=147&type=chunk) - The company's ability to retain key employees is a significant risk, exacerbated by a declining stock price that has left many stock options "underwater"; a recent option repricing was implemented to address this[158](index=158&type=chunk)[160](index=160&type=chunk) - The ongoing arbitration with Beam Therapeutics is highlighted as a material risk, as an adverse outcome could result in monetary damages and the loss of the company's AATD program[163](index=163&type=chunk) - The May 2025 strategic restructuring and workforce reduction may not achieve anticipated cost savings and could disrupt operations, reduce morale, and lead to further attrition[164](index=164&type=chunk)[165](index=165&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the three months ended June 30, 2025 - There were no unregistered sales of equity securities in the three months ended June 30, 2025[167](index=167&type=chunk) [Item 5. Other Information](index=39&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted, modified, or terminated Rule 10b5-1 trading plans during the three months ended June 30, 2025 - No directors or officers adopted, modified, or terminated a Rule 10b5-1 trading plan during the quarter[171](index=171&type=chunk) [Item 6. Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Quarterly Report on Form 10-Q, including officer certifications and various agreements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 1-31923 (IRS Employer Identification No.) 4225 East Windrose Drive, Suite 200 Phoenix, Arizona 85032 (Address of principal ...

Exhibit 99.1 QT Imaging Announces Continuous Strong Revenue Growth and Enhanced Balance Sheet in the Second Quarter 2025 Announces New 'QTI Cloud Platform' as it Accelerates Its Transformation into a Precision Imaging AI Company NOVATO, CA – Aug 7, 2025 – QT Imaging Holdings, Inc. (OTCQB: QTIH) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the three and six months end ...

Exhibit 99.1 QT Imaging Announces Continuous Strong Revenue Growth and Enhanced Balance Sheet in the Second Quarter 2025 Generated Revenue of $3.7 Million with 50% Gross Margin The Company Pursuing Uplisting to Nasdaq Addressed and Removed the Warrant Liability Through Amendments to the Lynrock Lake and Yorkville Warrant Agreements Announces New 'QTI Cloud Platform' as it Accelerates Its Transformation into a Precision Imaging AI Company NOVATO, CA – Aug 7, 2025 – QT Imaging Holdings, Inc. (OTCQB: QTIH) ("Q ...

Press Release UGI Reports Third Quarter Results August 6, 2025 VALLEY FORGE, PA - UGI Corporation (NYSE: UGI) today reported financial results for the fiscal quarter ended June 30, 2025. HIGHLIGHTS "We have achieved outstanding year-to-date results that showcase the strength of our asset portfolio and our team's commitment to safely and reliably deliver energy solutions to our customers," said Bob Flexon, President and Chief Executive Officer. "Our focus on driving superior business performance, operational ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-12647 OFG Bancorp (Exact name of registrant as specified in its charter) 254 Muñoz Rivera Avenue 0 ...